

ALERT



NicOx to present at the 28th Annual J.P. Morgan Healthcare Conference on January 14th

January 13th, 2010. Sophia Antipolis, France. www.nicox.com

Gavin Spencer, Vice President Business Development at NicOx, will present an overview on the Company's strategy and research and development programs at the 28th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14th, 2010 at 9:00 US PST (18:00 Central European Time – 17:00 UK Time).

The presentation will be uploaded on NicOx's website www.nicox.com on Thursday January 14th.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a pharmaceutical company focused on the research, development and future commercialization of drug candidates. NicOx is applying its proprietary nitric oxide-donating R&D platform to develop an internal portfolio of New Chemical Entities (NCEs) for the potential treatment of inflammatory, cardio-metabolic and ophthalmological diseases.

NicOx's lead investigational compound is naproxcinod, an NCE and a first-in-class CINOD (Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory drug candidate for the relief of the signs and symptoms of osteoarthritis. NicOx submitted a New Drug Application (NDA) for naproxcinod to the US Food and Drug Administration (FDA) in September 2009 and a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) in December 2009, following the successful completion of three pivotal phase 3 studies. The NDA for naproxcinod was accepted for filing by the FDA in November 2009 and the FDA has set a target date of July 24 2010, for the completion of its review.

In addition to naproxcinod, NicOx's pipeline includes several nitric oxide-donating NCEs, which are in development internally and with partners, including Merck & Co., Inc., for the treatment of widespread eye diseases, cardiometabolic diseases, hypertension and dermatological disease.

NicOx S.A. is headquartered in France and is listed on Euronext Paris (Compartment B: Mid Caps).



CONTACTS: <http://www.nicox.com>

NicOx: Karl Hanks • Director of Investor Relations and Corporate Communications
Tel +33 (0)4 97 24 53 42 • hanks@nicox.com

Media in the United States – FD: Robert Stanislaro • Tel +1 212 850 5657 • robert.stanislaro@fd.com
Irma Gomez-Dib • Tel +1 212 850 5761 • irma.gomez-dib@fd.com

Media in Europe - Citigate Dewe Rogerson: David Dible • Tel +44 (0)207 282 2949 • david.dible@citigatedr.co.uk
Nina Enegren • Tel: +44 (0)207 282 1050 • nina.enegren@citigatedr.co.uk